NextCure (NXTC) is trading down at $5.05 (-0.79%), as of the latest quote. It operates in the Health Care sector.
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | $6.35M | $22.4M | — | — | — | — | — |
| Growth (year over year) | — | — | +252.6% | — | — | — | — | — |
| Operating income | −$23.2M | −$37.5M | −$41.2M | −$70.8M | −$75.9M | −$67.6M | −$59.7M | −$57.6M |
| Operating margin | — | −590.5% | −184.2% | — | — | — | — | — |
| Net income | −$22.8M | −$33.7M | −$36.6M | −$69.4M | −$74.7M | −$62.7M | −$55.7M | −$55.8M |
| Net margin | — | −531.5% | −163.6% | — | — | — | — | — |
| EPS (diluted) | −$2396.16 | −$309.60 | −$15.96 | −$30.12 | −$32.28 | −$27.00 | −$23.88 | −$19.65 |
| Balance sheet | ||||||||
| Cash and equivalents | $135.2M | $34.1M | $32.8M | $12.3M | $26.6M | $13.1M | $27.7M | $26.0M |
| Total assets | $147.6M | $356.2M | $306.6M | $242.4M | $184.2M | $128.0M | $80.9M | $50.2M |
| Total liabilities | $32.3M | $34.7M | $12.9M | $9.00M | $16.6M | $13.6M | $15.4M | $15.2M |
| Long-term debt | $73.0K | $3.33M | $1.81M | $0 | $0 | — | — | — |
| Shareholders' equity | −$46.9M | $321.5M | $293.7M | $233.4M | $167.5M | $114.4M | $65.5M | $34.9M |
| Cash flow | ||||||||
| Operating cash flow | $7.99M | −$35.6M | −$45.0M | −$57.3M | −$53.9M | −$53.0M | −$40.8M | −$49.6M |
| Capital expenditure | $3.06M | $3.37M | $7.13M | $2.36M | $2.12M | $820.0K | $474.0K | — |
| Free cash flow | $4.93M | −$39.0M | −$52.1M | −$59.6M | −$56.0M | −$53.8M | −$41.3M | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$12.5M | −$12.5M | −$11.6M | −$27.3M | −$8.95M | −$9.76M | −$10.1M | −$15.1M |
| Net income | −$11.5M | −$11.6M | −$11.0M | −$26.8M | −$8.62M | −$9.44M | −$9.80M | −$14.9M |
| EPS (diluted) | −$4.95 | −$5.00 | −$4.70 | −$11.29 | −$3.22 | −$0.44 | −$1.87 | −$2.80 |
| Balance sheet | ||||||||
| Cash and equivalents | $27.7M | $27.7M | $21.8M | $4.89M | $7.32M | $26.0M | $15.2M | $15.3M |
| Total assets | $90.3M | $80.9M | $67.1M | $47.7M | $39.6M | $50.2M | $38.0M | $22.6M |
| Total liabilities | $14.8M | $15.4M | $11.3M | $16.0M | $16.0M | $15.2M | $11.3M | $10.5M |
| Shareholders' equity | $75.6M | $65.5M | $55.9M | $29.6M | $23.6M | $34.9M | $26.7M | $12.1M |
| Cash flow | ||||||||
| Operating cash flow | −$11.5M | −$6.97M | −$13.0M | −$22.7M | −$6.27M | −$7.64M | −$13.4M | −$9.71M |
| Capital expenditure | $170.0K | −$34.0K | — | — | — | — | — | — |
| Free cash flow | −$11.6M | −$6.93M | — | — | — | — | — | — |
From NextCure's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning NextCure in our feed yet.